Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Каталог · ЕАЭС

Клинические исследования и проекты

ГлаксоСмитКляйн ЛЛС · найдено 214

Ищем по всем вариантам написания в реестрах, по-русски и по-английски. Спонсор или разработчик.
Статус
Что исследуют
Источник
Фаза
Страна
Участники
Кто может участвовать По критериям ClinicalTrials.gov. Исследования, где реестр возраст и пол не указывает, тоже показываются. Возраст и пол нигде не сохраняются.
Сбросить
214 исследований
Завершено Фаза II Россия
GW685698X; placebo · ГлаксоСмитКляйн ЛЛС

A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250mcg Twice Daily Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma Symptomatic on Low-Dose ICS Therapy

622 участника во всех странах ClinicalTrials.gov FFA109685
Завершено Фаза III Россия
fluticasone furoate (FF); vilanterol (VI); umeclidinium bromide (UMEC) · ГлаксоСмитКляйн ЛЛС

A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

10 355 участников во всех странах ClinicalTrials.gov 116855
Завершено Фаза II Россия
GW642444M; Placebo · ГлаксоСмитКляйн ЛЛС

A Randomised, Double-blind, Placebo Controlled, Parallel Group, Dose Ranging Study Evaluating the Efficacy and Safety of GW642444M Administered Once Daily Compared With Placebo for 28 Days in Adolescent and Adult Subjects With Persistent Asthma

614 участников во всех странах ClinicalTrials.gov B2C109575
Завершено Фаза III Россия
eltrombopag; placebo · ГлаксоСмитКляйн ЛЛС

Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin)

759 участников во всех странах ClinicalTrials.gov TPL108390
Прекращено Фаза III Россия
ofatumumab; Placebo · ГлаксоСмитКляйн ЛЛС

A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Adult Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy

265 участников во всех странах ClinicalTrials.gov 110635
Прекращено Россия
115400 · ГлаксоСмитКляйн ЛЛС

A Prospective, Exploratory Observational Study Evaluating Specific Biomarkers in Primary Invasive Breast Cancer and Their Modulation by Standard Neoadjuvant Therapy

117 участников во всех странах ClinicalTrials.gov 115400
Прекращено Фаза III Россия
Ambrisentan 5 mg; Placebo · ГлаксоСмитКляйн ЛЛС

A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

33 участника во всех странах ClinicalTrials.gov 115811
Завершено Фаза III Здоровые добровольцы Россия
Synflorix™ · ГлаксоСмитКляйн ЛЛС

Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection

52 участника во всех странах ClinicalTrials.gov 115884
Завершено Фаза III Россия
Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg; Fluticasone Propionate 250mcg/ salmeterol 50mcg · ГлаксоСмитКляйн ЛЛС

A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

519 участников во всех странах ClinicalTrials.gov 113109
Завершено Фаза II Россия
SB497115 · ГлаксоСмитКляйн ЛЛС

A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy

183 участника во всех странах ClinicalTrials.gov 497115/003
Завершено Фаза III Россия
dutasteride 0.5mg once daily for 4 years; tamsulosin 0.4mg once daily for 4 years · ГлаксоСмитКляйн ЛЛС

A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical Outcome in Men With Moderate to Severe Symptomatic Benign Prostatic Hyperplasia

4 844 участника во всех странах ClinicalTrials.gov ARI40005
Завершено Фаза III Россия
albiglutide; sitagliptin; glimepiride; metformin; placebo albiglutide; placebo sitagliptin; placebo glimepiride · ГлаксоСмитКляйн ЛЛС

A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus

1 049 участников во всех странах ClinicalTrials.gov 112753
Завершено Фаза III Россия
fluticasone propionate; fluticasone propionate/salmeterol · ГлаксоСмитКляйн ЛЛС

A Randomized, Double-blind, Parallel Group Study Evaluating the Safety of Fluticasone Propionate/Salmeterol 100/50mcg HFA (2 Inhalations of 50/25mcg) Twice Daily Compared With Fluticasone Propionate 100mcg HFA (2 Inhalations of 50mcg) Twice Daily in Subjects 4-11 Years of Age With Persistent Asthma

351 участник во всех странах ClinicalTrials.gov SFA106484
Завершено Фаза III Россия
topotecan · ГлаксоСмитКляйн ЛЛС

An Open-Label, Multicentre, Randomised, Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non Small Cell Lung Cancer

760 участников во всех странах ClinicalTrials.gov 104864-A/387
Завершено Фаза II Россия
Pioglitazone; GW677954 · ГлаксоСмитКляйн ЛЛС

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus

448 участников во всех странах ClinicalTrials.gov ADG20001
Завершено Фаза III Россия
fluticasone furoate; albuterol/salbutamol · ГлаксоСмитКляйн ЛЛС

A Randomised, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Currently Receiving Mid to High Strength Inhaled Corticosteroids.

238 участников во всех странах ClinicalTrials.gov 114496
Завершено Фаза III Россия
FSC; Placebo · ГлаксоСмитКляйн ЛЛС

A Randomised, Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered Through a Capsule-Based Inhaler and a Multi-Dose Inhaler in Adults and Adolescents With Asthma

124 участника во всех странах ClinicalTrials.gov 115645
Завершено Фаза III Россия
FF/VI 100/25 Inhalation Powder NDPI; Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS; Placebo Inhalation Powder NDPI; Placebo Inhalation Powder ACCUHALER/DISKUS; Salbutamol as needed · ГлаксоСмитКляйн ЛЛС

A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

828 участников во всех странах ClinicalTrials.gov 116974

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.